Eric Lefkofsky And Tempus: Making Cancer Treatment More Affordable

Almost 40% of American adults face a cancer diagnoses. With 14.5 million Americans living with cancer, almost everyone knows someone touched by this terrible disease. Eric Lefkofsky and his company Tempus are making a difference by developing data enabled precision medicine. The company is transforming cancer care delivery by creating a platform to effectively analyze the clinical and molecular data of cancer patients. Their analytics software is making clinical and medical data more affordable and accessible.

Eric Lefkofsky learned about the problem with gaining access to and analyzing medical data when it was discovered his wife had breast cancer. Since then, Tempus, a company he co-founded, has been developing effective methods to streamline the process so doctors can quickly use the copious amount of information they have gathered. Tempus has developed software which turns relevant doctors’ notes into structured data for use in advancing the treatment and care of cancer patients. This will help doctors attack cancer at the cellular and molecular levels, use more effective medicines and treatments, and get better results.

Born in Southfield, Michigan, Eric Lefkofsky has an undergraduate degree from the University of Michigan and a juris doctor from the University of Michigan Law School. Since then he has co-founded a number of companies including Tempus and Groupon.com. Lefkofsky has lived in the Chicago area for many years. The headquarters of Tempus is located there. He has long been very deeply involved in the Chicago business community. Lefkofsky is Chicago’s Steppenwolf Theatre Company board of trustees chairman. He is also on the board of the Art Institute of Chicago and Chicago’s Lurie’s Children’s Memorial Hospital to learn more: https://www.bizjournals.com/chicago/news/2017/04/12/groupon-co-founder-moves-to-help-youth-access-art.html click here.

Eric Lefkofsky has been teaching in a number of Chicago area colleges for several years. He has taught at the Kellstadt Graduate School of Business at DePaul University as well as Northwestern University’s Kellogg School of Management. He is currently adjunct professor with the Booth School of Business at the University of Chicago.

In 2006, Eric Lefkofsky founded the Lefkofsky Foundation. The charitable trust is focused on children and supports educational, scientific and charitable causes and organizations worldwide.

Clay Siegall Achievements in Cancer Treatment

Clay B. Siegall is an influential figure in the oncology industry. Siegall established an institution known as Seattle Genetics in the year 1998, and he serves as the chairman and president. Clay Siegall is a scientist by training, and he specializes in cancer therapies. His passion for helping people with cancer motivated him to start Seattle Genetics.

Under his leadership, Seattle Genetics has done quite well. The company has developed several antibodies to treat cancer. One of the drugs from the company known as Adcetris has done very well on the international platform, and it being used in more than 65 nations. The company recently announced its plans to introduce better and affordable cancer treatment in the next five years.

As the chief executive and president of Seattle Genetics, Clay Siegall has entered into several strategic licenses for the ADC technologies. Some of the licenses have been signed with companies such as GlaxoSmithKline, AbbVie, Genentech and several others. Before starting the successful company, Siegall was working at an institution known as Bristol-Myers Squibb Pharmaceutical Research Institute. Clay also served in the national cancer institute, Alder BopPharmmaceutical, and several other establishments.

Dr. Clay Siegall has received several awards because of his achievements. In 2013, the successful scientist was given the prestigious University of Maryland Alumnus of the Year Award in Math, Computer, and Natural Sciences. Apart from his achievements at Seattle Genetics, Clay Siegall has authored over 70 publications. At the moment, Siegall also holds 15 patents. His educational background has played a fundamental role in his success too.

In an interview, Clay says that the idea of starting Seattle Genetics was born because of his passion for helping patients. When he was 19 years old, Clay’s father got cancer, and he watched it progress until he died. At the time of his death, Clay was still in school, and he understood the limited tools available to physicians who cure the disease. Because he wanted to improve the tools needed for cancer treatment, he went for his doctorate from the well-known George Washington University. While studying at the school, he learned the basics required to start the oncology company.